Summary

This AI-generated content is provided without warranty, with no liability accepted for reliance on it. Learn more.

• This summary is based on the review of two randomized controlled trial(s). ^[1-2]
• In the LOCK IT-100 trial, taurolidine/heparin significantly reduced the risk of catheter-related bloodstream infections (CRBSIS) compared to heparin alone, with 2% CRBSIs in the taurolidine/heparin group versus 8% in the heparin group. The hazard ratio was 0.29 (95% CI, 0.14 to 0.62), representing a 71% reduction in CRBSI risk (P < 0.001).
• In a trial involving high-risk neutropenic hematologic patients, taurolidine-citrate-heparin showed a trend toward reduced bacterial colonization compared to placebo (4.1% vs. 10.1%, RR = 0.41, 95% CI = 0.11 to 1.52), but this difference was not statistically significant. No significant differences were observed in secondary outcomes such as CRBSI incidence or catheter removal.
• In the LOCK IT-100 trial, the safety profile of taurolidine/heparin was comparable to heparin, with most treatment-emergent adverse events being mild or moderate. The Data and Safety Monitoring Board recommended early termination of the trial for efficacy, with no safety concerns.
• In the trial involving hematologic patients, no adverse events related to the administration of the taurolidine-citrate-heparin lock solution were reported, indicating a favorable safety profile compared to placebo.
• The LOCK IT-100 trial involved adults with kidney failure undergoing maintenance hemodialysis via CVC and showed that taurolidine/heparin significantly reduced the risk of catheter-related bloodstream infections (CRBSIS) compared to heparin alone. The trial involving hematologic patients included high-risk neutropenic patients with nontunneled CVCs, and while taurolidine-citrate-heparin showed a trend towards less bacterial colonization, it was not statistically significant. No significant differences in effectiveness were observed among subgroups within these populations.